Simpson Thacher & Bartlett advised Cisco Systems, Inc. on the offering, and Davis Polk & Wardwell advised the representatives of the underwriters. Cisco Systems, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Cooley advised Olema Pharmaceuticals, Inc. on the offering, and Davis Polk & Wardwell advised TD Cowen, as sales agent. Olema Pharmaceuticals ((“Olema”, Nasdaq: OLMA) announced its $150...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell, Maples and Calder and JunHe advised Credo Technology Group Holding Ltd on the offering. Credo Technology Group Holding Ltd (Nasdaq: CRDO) (“Credo”) announced...
You must be a Standard 1 Year member to access this content.
Cooley advised AN2 Therapeutics, Inc., and Davis Polk & Wardwell advised the joint book-running managers on the offering. AN2 Therapeutics, Inc. (Nasdaq:ANTX) announced a SEC-registered follow-on...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
You must be a Standard 1 Year member to access this content.
Davis Polk is advising Xponential Fitness on the offering, and Latham & Watkins is advising the underwriters involved. Xponential Fitness, Inc. has announced the pricing of...
You must be a Standard 1 Year member to access this content.
Cooley advised SiTime Corporation, while Davis Polk advised the sales agent, Stifel, Nicolaus & Company, in the offering. SiTime Corporation issued an SEC-registered at-the-market offering consisting of...
You must be a Standard 1 Year member to access this content.
Cooley advised AN2 Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. AN2 Therapeutics, Inc. announced its upsized initial public offering of...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Credo Technology Group Holding Ltd on the IPO while S&C represented the underwriters. Credo announced its $200 million initial public offering of 20,000,000 ordinary...
You must be a Standard 1 Year member to access this content.
